Last reviewed · How we verify
NCT03546075
The Impact of Acute Trans-resveratrol Administration on Whole Body Metabolism During Cognitive Demand.
NA trial testing Resveratrol in Cognitive Change in 27 participants. Completed in 18 December 2015.
18 December 2015
Quick facts
| Lead sponsor | Northumbria University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 27 |
| Start date | 7 May 2015 |
| Primary completion | 18 December 2015 |
| Estimated completion | 18 December 2015 |
Drugs / interventions tested
- Resveratrol — full drug profile →
- Placebo
Conditions studied
- Cognitive Change — all drugs for Cognitive Change →
Sponsor
Northumbria University
Who can join
Adults 18 to 35, any sex, with Cognitive Change. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: Increased cerebral vaso-dilation during cognitive demand is hypothesised to improve cognitive performance due to an improved micronutrient status. Despite previous research demonstrating that oral resveratrol can modulate cerebral haemodynamics, this has not translated into expected improvements to cognitive performance in young, healthy populations. As the brain is the most metabolic organ in the body, even subtle changes to fuel utilization and overall energy expenditure are detectable during cognitive demand. The measurement of both overall energy expenditure and fuel utilization may provide further insight to the effects of resveratrol and whether oral supplementation of this polyphenol can provide clear, cognitive benefits in a young, healthy sample. Objectives: The current study investigated the metabolic consequences of resveratrol on whole body metabolism and fuel oxidisation during cognitive performance. Methods: This repeated measures, double blind, placebo controlled, balanced design required participants (N=24 for metabolic activity \& N=26 for cognitive outcomes) to complete a serial subtraction demand battery at baseline, 45 minutes, 2 and 3 hours following 500 mg, 250 mg trans-resveratrol or inert placebo, on three separate occasions whilst connected to an on-line gas analysis system.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Stilbenes: a promising small molecule modulator for epigenetic regulation in human diseases.
Tian J, Jin L, Liu H, Hua Z. · · 2023 · cited 12× · PMID 38155902 · DOI 10.3389/fphar.2023.1326682
Verify or expand the search:
- PubMed search for NCT03546075
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Resveratrol
Trials testing the same drug.
- NCT06250283 — Resveratrol for the Prevention of Bone Loss in Postmenopausal Women · NA · completed
- NCT05808387 — The Effects of Resveratrol on Sirtuins and Apoptosis Biomarkers · NA · recruiting
- NCT06131918 — Assessment of Antioxidant Therapy on Oxidative Stress Biomarkers in Type 2 Diabetic Patients With Neuropathy · Phase 2 · completed
- NCT05653895 — Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS · NA · completed
- NCT05410093 — Clinical Efficacy Analysis of Resveratrol in the Treatment of Primary Ovarian Insufficiency · NA · unknown
Other recruiting trials for Cognitive Change
Currently open trials in the same condition.
- NCT07147894 — Executive Function Training for Children and Adolescents · NA · recruiting
- NCT07383324 — Heat Stress in Individuals With Schizophrenia · NA · recruiting
- NCT07261202 — Impact of Indoor Overheating on Physiological Strain in Children · NA · recruiting
- NCT07267598 — Suitability of a 26 °C Indoor Environment for Mitigating Heat Strain in Young Adults · NA · recruiting
- NCT07054723 — Surviving Daily Life · recruiting
Other Northumbria University trials
Trials by the same sponsor.
- NCT07501611 — Acute Cardiovascular Effects of Transcutaneous Auricular Vagus Nerve Stimulation · NA · not yet recruiting
- NCT07242430 — 12-week Multi-vitamin/Mineral Supplementation on Peri-menopause Symptoms, Cognition, Sleep, and Psychological Well-being · NA · not yet recruiting
- NCT07235878 — 12-week Magnesium Supplementation on Peri-menopause Symptoms, Cognition, Sleep, and Psychological Well-being · NA · not yet recruiting
- NCT07297485 — Evaluating the Level of Agreement Between Goniometer Measurements and Algorithm to Determine Wall Squat Position · completed
- NCT06967454 — Manipulation of Whey Permeate Formulation for Better Fluid Retention. · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03546075 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Northumbria University
- Last refreshed: 6 June 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03546075.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing